Evidence map›Paper›PMID 40963523›Full record

ArticleOncology letters2025

Novel biomarkers for prognosis in patients with localized prostate cancer.

Maria Goulielmaki, Savvas Stokidis, Theodoros Anagnostou, Angelos D Gritzapis, Ourania E Tsitsilonis, Constantin N Baxevanis, Sotirios P Fortis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria GoulielmakiCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.
Savvas StokidisCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.
Theodoros AnagnostouDepartment of Urology, Saint Savas Cancer Hospital, 11522 Athens, Greece.
Angelos D GritzapisCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.
Ourania E TsitsilonisSection of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece.
Constantin N BaxevanisCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.
Sotirios P FortisCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 11522 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcome for patients with localized prostate cancer (LPCa) is markedly variable, with different survival rates. The objective of the present study was to investigate how the levels of blood-related soluble factors and the densities of immune T-cell subsets could impact the prognosis of LPCa. The progression-free survival of 139 patients with LPCa was retrospectively analyzed after standard treatments. Survival was revealed to be associated with the levels of circulating HER-2/neu extracellular domain (HER-ECD), transforming growth factor β (TGFβ) and interleukin-8 (IL-8), as well as with the frequencies of total and prostate-specific antigen (PSA)-peptide-specific CD8

Indexed as

biosignatureCD8+ T-cell subsetsHER-2/neu extracellular domaininterleukin-8localized prostate cancersurvivaltransforming growth factor β

Identifiers

PMID40963523
PMCPMC12439455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.